# A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

> **NCT06412471** · PHASE2 · RECRUITING · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 235 (estimated)

## Conditions studied

- First-line Advanced NSCLC Patients

## Interventions

- **DRUG:** SSGJ-707
- **DRUG:** carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** paclitaxel
- **DRUG:** PD-1/L1
- **DRUG:** Paclitaxel-albumin

## Key facts

- **NCT ID:** NCT06412471
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-26
- **Primary completion:** 2025-07
- **Final completion:** 2025-08
- **Target enrollment:** 235 (ESTIMATED)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06412471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06412471, "A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06412471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*